New therapeutic agents for resistant Gram-positive infections.

about

Enterococcus faecalis phosphomevalonate kinase.Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus In vitro activity and killing effect of uperin 3.6 against gram-positive cocci isolated from immunocompromised patients.

P2860

Q33213455-753ADE85-9BE6-482F-8CDF-22FB95F70221 Q33935282-3107BB39-6531-4FAF-ACD9-29AB1A041AA8 Q42948091-574A2D1A-13B9-4249-841B-7294EE370890

P2860

New therapeutic agents for resistant Gram-positive infections.

Item

http://www.wikidata.org/entity/Q35917308

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

New therapeutic agents for resistant Gram-positive infections.

@ast

New therapeutic agents for resistant Gram-positive infections.

@en

type

Item

label

New therapeutic agents for resistant Gram-positive infections.

@ast

New therapeutic agents for resistant Gram-positive infections.

@en

prefLabel

New therapeutic agents for resistant Gram-positive infections.

@ast

New therapeutic agents for resistant Gram-positive infections.

@en

P1476

New therapeutic agents for resistant Gram-positive infections.

@en

P2093

Dillip Nathwani

http://www.w3.org/2001/XMLSchema#string

Hisham Ziglam

http://www.w3.org/2001/XMLSchema#string

P2860

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study.

Treatment options for vancomycin-resistant enterococcal infections.

Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program.

Correlation between consumption of antimicrobials in humans and development of resistance in bacteria.

Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections.

Glycopeptide resistance in coagulase-negative staphylococci.

Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects.

The incidence of and clinical variables associated with vancomycin-resistant enterococcal colonization in mechanically ventilated patients.

Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1.

Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001.

P304

655-665

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14787210.1.4.655

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2003-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15482162

http://www.w3.org/2001/XMLSchema#string

New therapeutic agents for resistant Gram-positive infections.

about

P2860

P2860

New therapeutic agents for resistant Gram-positive infections.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698